Date: 2013-09-16
Type of information: Private placement
Company: Therametrics, formerly known as Mondobiotech (Switzerland)
Investors:
Amount:
Funding type: private placement
Planned used:
Others: * On September 16, 2013, THERAMetrics, formerly known as Mondobiotech, has announced that the new shares which have been created in the course of the ordinary share capital increase as announced on 13 September 2013 have been issued and are listed and traded for the first time on the Main Standard of SIX Swiss Exchange (SIX). With the listing of the new shares on the Main Standard of SIX, the transaction announced on the 25 January 2013 concerning the business combination of THERAMetrics holding AG with Pierrel Research International AG is now completed.
* On September 13, 2013, THERAMetrics has announced that the Board of Directors has implemented the ordinary capital increase resolved by the Annual General Meeting of 20 June 2013. In the implementation of the ordinary share capital increase a total of 321\'786\'546 new registered shares of THERAMetrics holding AG have been issued. The total issued share capital of THERAMetrics holding AG is now CHF 3\'965\'575.25, with 396\'557\'525 registered shares. In connection with the implementation of the ordinary share capital increase, the authorized share capital of a maximum amount of CHF 1\'200\'000 resolved by the Annual General Meeting of 20 June 2013 has now been registered.
Last January, Pierrel and mondoBIOTECH have entered into a binding agreement for the combination of the Contract Research Organization (CRO) of Pierrel SpA with mondoBIOTECH. With the implementation of the ordinary capital increase, the business combination of THERAMetrics holding AG with Pierrel Research International AG has been completed. Pierrel Research International AG is now a 100% subsidiary of THERAMetrics holding AG. The new entity is a TCRDO (Technology driven Clinical Research & Development Organization) and targets a unique competitive edge in the rapidly growing and changing R&D outsourcing market. Leveraging a sophisticated technological platform for exploiting Drug Rescuing ad Repurposing opportunities and bringing a wide range of clinical research solutions including clinical development, investigational drug preparation (IMPs), Clinical Trials Phases I-IV, THERAMetrics employs over 260 people, operates globally with a presence in 20 countries with a particular focus in Eastern and Western Europe and the USA.
Therapeutic area:
